BACKGROUND: Higher body-mass index (BMI) has been implicated as a risk factor for developing pancreatic cancer, but its effect on survival has not been thoroughly investigated. The authors assessed the association of BMI with survival in a sample of pancreatic cancer patients and used epidemiologic and clinical information to understand the contribution of diabetes and hyperglycemia. METHODS: A survival analysis using Cox proportional hazards by usual adult BMI was performed on 1861 unselected patients with pancreatic adenocarcinoma; analyses were adjusted for covariates that included clinical stage, age, and sex. Secondary analyses incorporated self-reported diabetes and fasting blood glucose in the survival model. RESULTS: BMI as a continuous variable was inversely associated with survival from pancreatic adenocarcinoma (hazard ratio [HR], 1.019 for each increased unit of BMI [kg/m2], P<.001) after adjustment for age, stage, and sex. In analysis by National Institutes of Health BMI category, BMIs of 30 to 34.99 kg/m2 (HR, 1.14; 95% confidence interval [CI], 0.98-1.33), 35 to 39.99 kg/m2 (HR 1.32, 95% CI 1.08-1.62), and ≥40 (HR 1.60, 95% CI 1.26-2.04) were associated with decreased survival compared with normal BMI of 18.5 to 24.99 kg/m2 (overall trend test P<.001). Fasting blood glucose and diabetes did not affect the results. CONCLUSIONS: Higher BMI is associated with decreased survival in pancreatic cancer. Although the mechanism of this association remains undetermined, diabetes and hyperglycemia do not appear to account for the observed association.
BACKGROUND: Higher body-mass index (BMI) has been implicated as a risk factor for developing pancreatic cancer, but its effect on survival has not been thoroughly investigated. The authors assessed the association of BMI with survival in a sample of pancreatic cancerpatients and used epidemiologic and clinical information to understand the contribution of diabetes and hyperglycemia. METHODS: A survival analysis using Cox proportional hazards by usual adult BMI was performed on 1861 unselected patients with pancreatic adenocarcinoma; analyses were adjusted for covariates that included clinical stage, age, and sex. Secondary analyses incorporated self-reported diabetes and fasting blood glucose in the survival model. RESULTS: BMI as a continuous variable was inversely associated with survival from pancreatic adenocarcinoma (hazard ratio [HR], 1.019 for each increased unit of BMI [kg/m2], P<.001) after adjustment for age, stage, and sex. In analysis by National Institutes of Health BMI category, BMIs of 30 to 34.99 kg/m2 (HR, 1.14; 95% confidence interval [CI], 0.98-1.33), 35 to 39.99 kg/m2 (HR 1.32, 95% CI 1.08-1.62), and ≥40 (HR 1.60, 95% CI 1.26-2.04) were associated with decreased survival compared with normal BMI of 18.5 to 24.99 kg/m2 (overall trend test P<.001). Fasting blood glucose and diabetes did not affect the results. CONCLUSIONS: Higher BMI is associated with decreased survival in pancreatic cancer. Although the mechanism of this association remains undetermined, diabetes and hyperglycemia do not appear to account for the observed association.
Authors: A G Bais; I Beckmann; J Lindemans; P C Ewing; C J L M Meijer; P J F Snijders; T J M Helmerhorst Journal: J Clin Pathol Date: 2005-10 Impact factor: 3.411
Authors: Rachael Z Stolzenberg-Solomon; Barry I Graubard; Suresh Chari; Paul Limburg; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes Journal: JAMA Date: 2005-12-14 Impact factor: 56.272
Authors: Mark T Whary; Nataliya Sundina; Luis E Bravo; Pelayo Correa; Francisco Quinones; Fanny Caro; James G Fox Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-06 Impact factor: 4.254
Authors: P Pellegrini; A M Berghella; T Del Beato; S Cicia; D Adorno; C U Casciani Journal: Cancer Immunol Immunother Date: 1996-01 Impact factor: 6.968
Authors: S E Hankinson; W C Willett; J E Manson; D J Hunter; G A Colditz; M J Stampfer; C Longcope; F E Speizer Journal: J Natl Cancer Inst Date: 1995-09-06 Impact factor: 13.506
Authors: Jason A Willis; Sara H Olson; Irene Orlow; Semanti Mukherjee; Robert R McWilliams; Robert C Kurtz; Robert J Klein Journal: Clin Cancer Res Date: 2012-06-04 Impact factor: 12.531
Authors: Joao Incio; Josh Tam; Nuh N Rahbari; Priya Suboj; Dan T McManus; Shan M Chin; Trupti D Vardam; Ana Batista; Suboj Babykutty; Keehoon Jung; Anna Khachatryan; Tai Hato; Jennifer A Ligibel; Ian E Krop; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Masabumi Shibuya; Peter Carmeliet; Raquel Soares; Dan G Duda; Rakesh K Jain; Dai Fukumura Journal: Clin Cancer Res Date: 2016-02-09 Impact factor: 12.531
Authors: Clement L K Chia; Anthea Y S Lee; Vishal G Shelat; Saleem Ahmed; Sameer P Junnarkar; Winston W L Woon; Jee-Keem Low Journal: Hepatobiliary Surg Nutr Date: 2016-02 Impact factor: 7.293
Authors: Joao Incio; Hao Liu; Priya Suboj; Shan M Chin; Ivy X Chen; Matthias Pinter; Mei R Ng; Hadi T Nia; Jelena Grahovac; Shannon Kao; Suboj Babykutty; Yuhui Huang; Keehoon Jung; Nuh N Rahbari; Xiaoxing Han; Vikash P Chauhan; John D Martin; Julia Kahn; Peigen Huang; Vikram Desphande; James Michaelson; Theodoros P Michelakos; Cristina R Ferrone; Raquel Soares; Yves Boucher; Dai Fukumura; Rakesh K Jain Journal: Cancer Discov Date: 2016-05-31 Impact factor: 39.397